Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: J Pharm Sci. 2017 Oct 31;107(1):113–120. doi: 10.1016/j.xphs.2017.10.033

Table 2.

Solubility product (Ksp), intrinsic solubility (S0,CC), and solubility advantage ( SA=S0,CC or S0,SaltS0,LTG) of LTG cocrystals and salts.

Solid Phase Ksp (M2) S0,CC or S0,Salt (M) SA
LTG-NCT Cocrystal (1.4±0.4) ×10−4 1.2 × 10−2 18
LTG-HCl Salt (6.7±0.53) × 10−5 a 8.2 × 10−3 12
LTG-SAC Salt (1.1±0.2) × 10−5 3.3 × 10−3 5
LTG-MP Cocrystal (5.3±0.47) × 10−7 b 7.3 × 10−4 1.1
LTG-PB Cocrystal (1.2±0.5) × 10−8 1.1 × 10−4 0.2
a

Ksp of LTG-HCl was calculated from reported solubility of 0.46 mg/mL at 37°C (pH 1.2) from reference27. Ksp of the salt was estimated at 25°C from [LTGH+] and [Cl] concentrations calculated from the dissolved salt and HCl concentrations, using a heat of solution value of 30 kJ/mol.

b

Steady state concentration from dissolution data in reference (3) was used to calculate the Ksp of lamotrigine-methylparaben (LTG-MP) cocrystal, where cocrystal was reported to be stable.